BioHarvest Sciences (BHST) Stock Price, News & Analysis

Company Overview

BioHarvest Sciences Inc. is a biotechnology company developing and commercializing products made with its proprietary Botanical Synthesis technology. The company’s platform is designed to produce specific plant-based compounds, including polyphenols, without growing the entire plant. BioHarvest says the process may help generate consistent, standardized botanical ingredients for use in health and wellness products and pharmaceutical development.

The company’s principal commercial product is VINIA, a powdered whole-fruit botanical ingredient derived from red grape cells and marketed for its polyphenol content. VINIA is offered through dietary supplements and related consumer health products. BioHarvest also has a pharmaceutical development program focused on applying its technology to potential therapeutic products, including investigational psychedelic-based treatments.

BioHarvest Sciences was founded in 2007 and is headquartered in Vancouver, British Columbia. The company serves consumers through direct and online sales channels and markets its products internationally, while its research and development activities support potential applications in global pharmaceutical and health-care markets. Ilan Sobel serves as chief executive officer.

Key Stats

• Today's Range: $1.45 to $1.51
• 50-Day Range: $1.46 to $2.83
• 52-Week Range: $1.45 to $12.80
• Volume: 1,421 shs
• Average Volume: 36,921 shs
• Market Capitalization: $29.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.50
• Consensus Rating: Hold

BioHarvest Sciences Stock Analysis - MarketRank™

BioHarvest Sciences scored higher than 52% of companies evaluated by MarketBeat, and ranked 104th out of 171 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

BioHarvest Sciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

BioHarvest Sciences has a consensus price target of $6.50, representing about 345.2% upside from its current price of $1.46.

Amount of Analyst Coverage

BioHarvest Sciences has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioHarvest Sciences are expected to grow in the coming year, from ($0.58) to ($0.42) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioHarvest Sciences is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioHarvest Sciences is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioHarvest Sciences has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.38% of the float of BioHarvest Sciences has been sold short.

Short Interest Ratio / Days to Cover

BioHarvest Sciences has a short interest ratio ("days to cover") of 1.95, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioHarvest Sciences has recently increased by 1.34%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioHarvest Sciences does not currently pay a dividend.

Dividend Growth

BioHarvest Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for BioHarvest Sciences this week, compared to 3 articles on an average week.

MarketBeat Follows

1 people have added BioHarvest Sciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioHarvest Sciences insiders have not sold or bought any company stock.

Percentage Held by Institutions

BioHarvest Sciences has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 9/24/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Consumer Staples
• Industry: Personal Care Products
• Sub-Industry: Personal Care Products
• Current Symbol: NASDAQ:BHST
• Previous Symbol: NASDAQ:BHST
• CIK: 1723464
• Web: bioharvest.com
• Phone: 646-863-2177
• Fax: N/A
• Employees: 89
• Year Founded: N/A

Price Target and Rating

• Average Price Target for BioHarvest Sciences: $6.50
• High Price Target: $8.00
• Low Price Target: $5.00
• Potential Upside/Downside: +331.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.14 million
• Net Margins: -31.21%
• Pretax Margin: -30.94%
• Return on Equity: -58.30%
• Return on Assets: -25.60%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.24
• Quick Ratio: 1.75

Sales & Book Value

• Annual Sales: $34.51 million
• Price / Sales: 0.86
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.30 per share
• Price / Book: 1.16

Miscellaneous

• Outstanding Shares: 19,620,000
• Free Float: N/A
• Market Cap: $29.59 million
• Optionable: N/A
• Beta: 0.94